TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02289027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for cAd3-EBOZ vaccine)
Description: Diluent
Study: NCT01899482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Study: NCT01418352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablets once weekly for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablets once weekly for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole tablets once weekly for 8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Aripiprazole matching-placebo once-weekly for 8 weeks.
Study: NCT04543305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRT1419
Description: PRT1419 will be administered orally
Study: NCT00707122

Intervention type: OTHER
Group type: OTHER
Intervention: Albumin and Crystalloids
Description: From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:~1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:~1. if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;~2. if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;~3. if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted.

Intervention type: OTHER
Group type: OTHER
Intervention: Crystalloids
Description: Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.~control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed.
Study: NCT01899482

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Behavioral education.
Study: NCT01595919

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Intervention
Description: Ad libitum amounts of beverage at a meal
Study: NCT01899482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Behavioral education.
Study: NCT04189978

Intervention type: DIAGNOSTIC_TEST
Intervention: Clinical evaluation
Description: The assessment is based on a comprehensive questionnaire, a simple clinical examination, an spirometry test, allergic skin tests, measurement of the exhaled fraction of NO (FeNO) and blood serum analysis.
Study: NCT04212182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: HFNC provides warmed and humidified gas administered through slightly enlarged nasal prongs.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NPPV
Description: NPPV is the standard therapy for ventilatory failure in AECOPD.
Study: NCT02272582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOMVC001 Vascular Conduit Solution
Description: SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care Heparin-dosed saline
Description: SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
Study: NCT01038882

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of \>2 min to maintain conscious sedation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological serum
Description: We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
Study: NCT01221519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: 3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
Study: NCT04666493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT), specifically using the Facing Your Fears (FYF) curriculum
Description: The Facing Your Fears program (FYF; Reaven et al. 2011) is a CBT-based group treatment program that has been adapted for the needs of children with high-functioning ASD. The current project will adapt the FYF program for virtual delivery and examine its effectiveness.
Study: NCT02742727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD7 CAR-pNK cells
Description: The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
Study: NCT00023829

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: flutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: releasing hormone agonist therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: releasing hormone agonist therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT05378711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Children will receive a placebo or fluoxetine at different times dependent upon random assignment to a treatment schedule.
Study: NCT01897584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: inverse IE
Description: in only one group changes of I:E ratio would be applied
Study: NCT03577002

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serious Illness Care Program (SICP)
Description: SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Serious Illness Care Program (SICP)
Description: SICP includes the Serious Illness Conversation Guide, which provides patient-tested language for initial and follow-up conversations; training materials, including didactic materials and case studies for structured role playing; and implementation guidance including recommended approaches to identifying appropriate patients and templates for documentation of conversations
Study: NCT03867877

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodized training with motor practice
Description: Exercises at 75-80% of the subject's maximum for strength exercise using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day with high-speed concentric and 2 second eccentric contractions, and exercises that simulate activities of daily living for the motor practice day. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes warm-up, 50 minutes of training and five minutes of cool-down.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simple Periodized Training
Description: Exercises at 75-80% of the subject's maximum for strength using contractions with 2 second concentric and 3 second eccentric for the strength day. 30-80% of subjects' maximal strength for the power day, with high speed concentric and 2 second eccentric contractions, and for hypertrophy day at 60-75% of subjects' maximum strength. All resistance-training will be performed on Keiser air-driven machines. Subjects will perform 10 exercises targeting all major muscle groups. The training will last for 12 consecutive weeks, for a total of 36 visits. Each visit will be approximately 60 minutes long and will consist of 5 minutes exercise using contractions warm-up, 50 minutes of training and five minutes of cool-down.
Study: NCT00877448

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Multimeric-001 250 Mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric-001 250 Mcg

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Phosphate Buffered saline

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvanted PBS

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted Multimeric-001 500 Mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric-001 500 Mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multimeric-001 125 Mcg
Study: NCT01517451

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy (ADT)
Description: Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
Study: NCT04076228

Intervention type: DRUG
Intervention: Pembrolizumab
Description: pembrolizumab is a PD-1 inhibitor. Treatment and follow up will be performed at Kiang Wu Hospital in their clinical oncology center. Clinically pathological related information will be recorded.
Study: NCT00096135

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given subcutaneously (SC)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: given subcutaneously (SC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV over 15-30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: IV over 15-30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: IV over 3 hours twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: IV over 3 hours twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: IV over 15 minutes
Study: NCT03379428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg
Description: 560 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 840 mg
Description: 840 mg by mouth daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg
Description: 420 mg by mouth daily
Study: NCT04248881

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Lifestyle Education
Description: Healthy lifestyle information (education) is distributed to participants during the World Cancer Day Walk via brochure, lectures, and professional counseling.
Study: NCT00096135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: IV over 15 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: oral twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: IV over 1 hour

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: rescue IV over 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: rescue IV over 24 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: intramuscularly (IM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: intramuscularly (IM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: intramuscularly (IM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: intramuscularly (IM)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: therapeutic hydrocortisone
Study: NCT02160548

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Standard management for OP poisoning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard care+ 2.5 mg Salbutamol
Description: Ventolin respiratory solution 2.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard care+ 5 mg Salbutamol
Description: Ventolin respiratory solution 5 mg
Study: NCT00096135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: given IV
Study: NCT02226809

Intervention type: DEVICE
Intervention: Accelerometry
Description: Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
Study: NCT00423488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg
Description: 1 x 10-mg tablet, provided as blinded study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: 1 x 20-mg tablet, provided as open-label study treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg
Description: 1 x 20-mg tablet, provided as open-label study treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe Placebo
Description: 1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin 20 mg
Description: 1 x 20-mg tablet, provided as blinded study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin Placebo
Description: 1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
Study: NCT01140620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
Study: NCT00096135

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
Study: NCT01140620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
Study: NCT02961140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac Output Maximization
Description: According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
Study: NCT00771238

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P500 Mattress
Description: Study mattress
Study: NCT01221519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: 3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: 3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
Study: NCT01568892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg twice daily
Description: Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg twice daily
Description: Active dolutegravir plus failing background regimen (Day 1 to Day 7). Open label dolutegravir plus optimized background regimen (from Day 8)
Study: NCT01140620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: risperidone (2 mg) capsule. One dosing of 2 mg.
Study: NCT01568892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir placebo twice daily
Description: Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
Study: NCT01955278

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Definitive end colostomy with mesh
Description: In the mesh group, a synthetic prosthetic mesh low weight type Ultrapro (15x15 cm) will be used. It will be placed in a sublay position between the rectus abdominis muscle and the posterior rectus sheath, will be sutured to the posterior rectus sheath with absorbable multifilament stitches. Once positioned and fixed the mesh the bowel will be brought out through a cross cut in the center of the mesh Finally, colon will be fixed by colocutaneous end to end absorbable multifilament sutures.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional definitive end colostomy
Study: NCT02045264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant (30 mg)
Description: On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
Study: NCT02539940

Intervention type: DEVICE
Intervention: Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV
Description: Angioplasty for revascularization in below-the-knee arteries
Study: NCT01140620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: risperidone (2 mg) capsule. One dosing of 2 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline infusion. Duration approximately 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: saline infusion. Duration approximately 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo risperidone
Description: placebo capsule to match risperidone 2 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo risperidone
Description: placebo capsule to match risperidone 2 mg capsule
Study: NCT00525564

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo diskus inhalation powder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol diskus inhalation powder
Description: 50 micrograms twice a day
Study: NCT01586117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifostine
Description: intrarectal Amifostine administration 1500mg QD x 5 weeks
Study: NCT00913588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)
Study: NCT01837420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201 80mg

Intervention type: DRUG
Group type: OTHER
Intervention: VB-201 160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201 160mg

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study: NCT04397354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intracochlear Dexamethasone
Description: intracochlear injection of dexamethasone with cochlear implantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intratympanic Dexamethasone
Description: intratympanic injection of dexamethasone with cochlear implantation

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: No additional drugs(control Group)
Description: Control group: No drugs will be injected middle ear with cochlear implantation